Agilon Health (NYSE:AGL) Stock Price Down 5.1% – Time to Sell?

Agilon Health, Inc. (NYSE:AGL)’s stock price was down 5.1% on Tuesday . The company traded as low as $81.95 and last traded at $81.97. Approximately 107,183 shares changed hands during trading, a decline of 71% from the average daily volume of 365,729 shares. The stock had previously closed at $86.39.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. JPMorgan Chase & Co. cut shares of Agilon Health from a “neutral” rating to an “underweight” rating and set a $21.00 price target for the company. in a research report on Monday, May 4th. Wells Fargo & Company reissued an “overweight” rating and issued a $72.00 price target (up from $37.50) on shares of Agilon Health in a research report on Friday, May 8th. Benchmark reissued a “buy” rating and issued a $95.00 price target (up from $13.00) on shares of Agilon Health in a research report on Thursday, May 21st. Weiss Ratings cut shares of Agilon Health from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday. Finally, Citigroup reissued a “neutral” rating and issued a $80.00 price target (up from $18.75) on shares of Agilon Health in a research report on Friday, May 15th. Five investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $58.73.

Agilon Health Price Performance

The stock’s fifty day moving average price is $38.02 and its two-hundred day moving average price is $24.36. The firm has a market capitalization of $1.50 billion, a price-to-earnings ratio of -4.18 and a beta of 2.29. The company has a current ratio of 1.04, a quick ratio of 1.04 and a debt-to-equity ratio of 0.08.

Agilon Health (NYSE:AGL) last announced its quarterly earnings data on Wednesday, May 6th. The company reported $1.80 earnings per share for the quarter, beating analysts’ consensus estimates of $1.04 by $0.76. Agilon Health had a negative net margin of 6.09% and a negative return on equity of 146.03%. The business had revenue of $1.42 billion for the quarter, compared to analyst estimates of $1.38 billion. Equities research analysts expect that Agilon Health, Inc. will post -3.75 EPS for the current year.

Institutional Investors Weigh In On Agilon Health

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Alpine Global Management LLC acquired a new stake in Agilon Health during the 4th quarter worth $84,000. Invesco Ltd. raised its stake in Agilon Health by 30.7% during the 4th quarter. Invesco Ltd. now owns 1,004,266 shares of the company’s stock worth $692,000 after acquiring an additional 235,951 shares in the last quarter. Mercer Global Advisors Inc. ADV acquired a new stake in Agilon Health during the 4th quarter worth $86,000. Numerai GP LLC raised its stake in Agilon Health by 207.3% during the 4th quarter. Numerai GP LLC now owns 1,228,071 shares of the company’s stock worth $846,000 after acquiring an additional 828,472 shares in the last quarter. Finally, Odyssean LLC acquired a new stake in Agilon Health during the 4th quarter worth $96,000.

About Agilon Health

Agilon Health (NYSE: AGL) is a healthcare company that partners with independent primary care physicians to deliver value-based care for Medicare beneficiaries. Through risk-sharing arrangements, Agilon assumes financial responsibility for patient populations, enabling physicians to focus on preventive and proactive health management. The company provides the administrative, clinical and operational infrastructure needed to support comprehensive care delivery.

Agilon’s platform encompasses data analytics, care management, patient engagement tools and population health programs.